
Kosmos 482: Out-of-control Russian spacecraft probably just fell to Earth, experts say
An out-of-control Russian spacecraft has probably plummeted to Earth, after 53 years stuck in orbit, experts say.
In recent weeks, the spacecraft known as Kosmos 482 has been making an uncontrolled approach towards Earth. Experts have been tracking it since – though they noted that it was very unlikely that it would land over a populated era.
Now, the European Space Agency and others say the spacecraft has most likely hit the Earth. It was not spotted on its most recent pass over radar in Germany, the agency said, and predictions based on its orbit and previous location suggest that it would probably have already fallen to Earth.
As of Saturday morning, the US Space Command had yet to confirm the spacecraft's demise as it collected and analysed data from orbit.
But it remains unclear when and where exactly it dropped down.
The spacecraft was originally made to land on Venus, and was built to survive the extreme atmosphere there.
But it was hit by technical problems during its launch, and got stuck in orbit around Earth. For the 53 years since, it has been floating around our planet until its orbit collided with the Earth.
Since the spacecraft was made to land on the hot and high-pressure planet of Venus, experts have speculated that it could have survived the descent through Earth's atmosphere, rather than breaking up like many other uncontrolled descents.
But experts said it was likely to come down over water, covering most of the world, or a desolate region.
The odds of it slamming into a populated area are 'infinitesimally small', said University of Colorado Boulder scientist Marcin Pilinski.
'While we can anticipate that most of this object will not burn up in the atmosphere during re-entry, it may be severely damaged on impact,' Mr Pilinski said.
By Friday, all indications pointed to a re-entry early on Saturday morning, US Eastern Time, give or take several hours.
While space debris trackers around the world converged in their forecasts, it was still too soon to know exactly when and where the spacecraft known as Kosmos 482 would come down.
That uncertainty was due to potential solar activity and the spacecraft's old condition.
Its parachutes were expected to be useless by now and its batteries long dead.
Dutch scientist Marco Langbroek estimated the impact speed at 150mph if the spacecraft remains intact.
The Soviets launched Kosmos 482 in 1972, intending to send it to Venus to join other spacecraft in their Venera programme.
But a rocket malfunction left this one stuck in orbit around Earth.
Gravity kept tugging on it and was expected to finally cause its doom.
Spherical in shape, the spacecraft – 3ft (one metre) across and packing more than 1,000lb (495kg) – will be the last piece of Kosmos 482 to fall from the sky.
All the other parts plummeted within a decade.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
an hour ago
- The Independent
Diet containing foods with this key component can lead to longer life, study finds
A diet containing daily servings of tea, berries, apples, oranges or grapes may lower the risk of early death and promote longevity. A new study published in the journal Nature Food concludes that people who consume a diverse range of foods rich in flavonoid molecules may have a lower risk of developing chronic health conditions and a higher potential to live longer. Consuming flavonoid food sources in the form of tea, berries, dark chocolate, and apples can prevent the development of conditions like type 2 diabetes, cancer and heart and neurological diseases, scientists, including from Queen's University Belfast, say. 'We have known for some time that higher intakes of dietary flavonoids, powerful bioactives naturally present in many foods and drinks, can reduce the risk of developing heart disease, type 2 diabetes as well as neurological conditions like Parkinson's,' study co-author Aedín Cassidy explains. 'We also know from lab data and clinical studies that different flavonoids work in different ways, some improve blood pressure, others help with cholesterol levels and decrease inflammation.' Flavonoid molecules are found abundantly in blueberries, strawberries, oranges, apples, grapes, and even tea, red wine and dark chocolate. 'Flavonoid intakes of around 500mg a day were associated with a 16 per cent lower risk of all-cause mortality as well as a 10 per cent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease,' Benjamin Parmenter, another author of the study, says. 'That's roughly the amount of flavonoids that you would consume in two cups of tea.' The study, which involved tracking over 120,000 people aged 40 to 70 for over a decade, is the first of its kind to highlight a benefit to consuming a diverse range of flavonoids beyond simply consuming a high quantity. The findings indicate consuming a higher quantity and a wider diversity of flavonoid foods can lead to a greater reduction in ill health than just a single source. The research is in line with the popular belief that eating colourful foods is invaluable to maintaining good health. 'Eating fruits and vegetables in a variety of colours, including those rich in flavonoids, means that you are more likely to get the vitamins and nutrients you need to sustain a healthier lifestyle,' study author Tilman Kuhn says. 'The results provide a clear public health message,' says Dr Cassidy, 'suggesting that simple and achievable dietary swaps, like drinking more tea and eating more berries and apples, can help increase the variety and intake of flavonoid-rich foods, and potentially improve health in the long term.'


Daily Mail
7 hours ago
- Daily Mail
Urgent warning over new Covid-19 variant that 'experts fear is more infectious' with case numbers growing in Britain
An urgent warning has been issued over a new Covid-19 variant that experts suggest could be more infectious than previous strains, with case numbers on the rise in Britain. The NB.1.8.1 variant has been found in 22 countries, including the UK, since it emerged in January, with cases recorded in Wales over the last few months, Wales Online reports. It has also been tracked in popular British tourist hotspots, including Thailand, the Maldives and Egypt, with soaring cases also seen in Ireland, the US, Australia and parts of Europe. Indeed, a whopping 257,280 Covid-19 cases have been recorded in Thailand this year, including 52 deaths, prompting an official warning from health authorities about the new variant. And some experts 'fear the strain is more infectious' than its predecessors, leading to rapidly rising numbers. Subhash Verma, professor of microbiology and immunology at the University of Nevada, Reno School of Medicine, told CBS News: 'Data indicates that NB.1.8.1 does not lead to more severe illness compared to previous variants, although it appears to have a growth advantage, suggesting it may spread more easily. 'In other words, it is more transmissible.' The World Health Organisation (WHO) claimed that, using the evidence available, NB.1.8.1's threat to the public health was 'low at the global level'. The body added: 'Currently approved Covid-19 vaccines are expected to remain effective to this variant against symptomatic and severe disease.' But it still issued an official warning about the strain, part of the Omicron variant, branding it a 'variant under monitoring' thanks to key mutatations and its global spread. It said: 'Despite a concurrent increase in cases and hospitalisations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation.' There are not currently any travel restrictions associated with the variant and the WHO does not recommend any such measures. Of the 22 countries where it had been recorded by late April, the variant constitutes around 10.7 per cent of all submitted strains, flying up from just 2.5 per cent four weeks before. The WHO particularly emphasised its prevalence in Europe, the Western Pacific region - which includes Asia and Australia - and North and South America. Professor Laura Herrero of Griffith University, Australia explained that the strain had become the dominant variant in China and Hong Kong by the end of April. She said: 'Common symptoms [of NB.1.8.1] include sore throat, fatigue, fever, mild cough, muscle aches and nasal congestion. 'Gastrointestinal symptoms may also occur in some cases. 'The WHO has not yet observed any evidence it causes more severe disease compared to other variants. 'Reports suggest symptoms of NB.1.8.1 should align closely with other Omicron subvariants.' As always, NHS guidance says that if you are experiencing Covid symptoms, you can protect yourself and others by staying at home and avoiding contact with other people for five days after a positive test, and three days if you or you child are under 18.


Daily Mail
8 hours ago
- Daily Mail
Major study finds 90p supplement could slash risk of sudden heart death: 'Reverses' signs of deadly disease
A cheap supplement could help prevent potentially deadly heart failure among patients with type 2 diabetes, research suggests. More than 5million people in the UK are thought to suffer from type 2 diabetes, which is often referred to as a 'silent killer', with rates having soared in recent years. But now scientists have found patients taking a substance called mitoquinone—sold as a health supplement for about 90p per tablet—had healthier hearts than those in a control group. Scientists behind the study said the results could save lives given how patients with type 2 diabetes have five times the risk of suffering heart failure compared to someone without the condition. In the trial, patients on mitoquinone even had signs that the damage their hearts had suffered from diabetes had been 'reversed'. However, experts have said while their findings are promising they now need to be backed up by larger trials. Mitoquinone is an artificial antioxidant—a substance that helps protect cells—which is a modified version of an antioxidant naturally found in the body called CoQ10. Dr Henry Procter, an expert in heart health at University of Leeds and lead author of the four month study, said the results were 'encouraging'. 'If the study had continued for longer, it is likely we would have started to see differences in more serious indicators of heart health between the group with mitoquinone and the group without,' he said. 'We hope that a larger study will continue to demonstrate the benefits of this antioxidant, and that one day soon diabetic patients can be prescribed it to help prevent heart failure before it ever affects their lives.' In the trial, the results of which were presented at the British Cardiovascular Society conference in Manchester, involved 70 patients with type 2 diabetes without heart failure. Half were given 40mg of mitoquinone per day in addition to their regular diabetes treatment, while the other half just received their usual medication. Both groups had their heart health assessed at the start of the study and again four months later. At the end of the trial the group on mitoquinone were found to have hearts that performed 15 per cent more efficiently than at the start of the study. The mitoquinone group were also found to have improvements in exercise tests, with their hearts also able to relax more quickly after exertion. Researchers said these were signs that the stress and stiffness the organ suffers from diabetes had been reversed. Diabetes damages the heart by interfering with how the organ processes and uses energy. Over time this interference causes stress and harms the cells of the heart muscle, leading to it becoming stiff and having to work harder to pump blood around the body, increasing the risk of heart failure. Mitoquinone is thought to help protect the cells from this damage. The substance is sold online as a health supplement for about £50 for a jar of 60 pills, which works out at about 86p per tablet. However, these are at doses far lower than those used in the study. Critically, no adverse side effects were reported in the group taking mitoquinone. The scientists are now hoping to run another similar trial with a larger group of patients to add more weight to their findings. If the results are supported by future studies the experts hope diabetes patients could one day be prescribed mitoquinone to help protect their hearts for longer. Heart failure is an incurable condition where the organ can't pump blood around the body as well as it should. The condition tends to get worse over time and is often eventually fatal. Once a diabetes patient is diagnosed with heart failure it triples their risk of dying within the next five years. Reacting to the study, Professor Bryan Willians, chief scientific and medical officer at the charity the British Heart Foundation, said it was a promising start. 'It's still early days for this research and the results will need to be confirmed in a larger scale trial,' he said. 'The study neatly demonstrates why it is so important to continue to support research and look for solutions in a wide variety of places, so that we can continue to offer hope to people living with, and at risk of, cardiovascular disease.' Almost 6million Britons have diabetes, of which 90 per cent is type 2, but charities estimate 1.2million are living with the disease undiagnosed. While nationally, an estimated 8 per cent of the population of England has the disease, this rises to over one in 10 people in some parts of the country. Type 2 diabetes occurs when the body doesn't make enough insulin or the insulin it makes doesn't work properly. Insulin is a hormone critical to controlling blood sugar levels. Having high blood sugar levels over time can cause heart attacks and strokes, as well as problems with the eyes, kidneys and feet. Sufferers may need to overhaul their diet, take daily medication and have regular check-ups. Symptoms of the condition, which is diagnosed with a blood test, include excessive thirst, tiredness and needing to urinate more often. But many people have no signs.